Recent News

• 01.27.2026 - Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
• 01.12.2026 - Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
• 01.05.2026 - Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
• 12.18.2025 - Tyrer-Cuzick and the MyRisk Hereditary Cancer Test® with RiskScore®: Risk Assessment Tools for a Smarter, Personalized Approach to Breast Cancer Screening
• 12.09.2025 - Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
• 11.25.2025 - Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
• 11.13.2025 - More Than Just Risk: Genetic Testing Is Shaping Breast Cancer Treatment
• 11.11.2025 - Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
• 11.10.2025 - Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
• 11.06.2025 - One Visit. Lasting Impact. – A MyRisk® Provider Story

Recent Filings

• 01.13.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.12.2026 - 8-K Current report
• 01.12.2026 - EX-99.1 EX-99.1
• 01.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.04.2025 - 4 Statement of changes in beneficial ownership of securities